Accession Number: | 0000899243-20-014612 |
Date: | 2020-05-27 |
Issuer: | AIMMUNE THERAPEUTICS, INC. (AIMT) |
Original Submission Date: |
ENRIGHT PATRICK G
C/O LONGITUDE CAPITAL PARTNERS II, LLC
2740 SAND HILL ROAD, SECOND FLOOR
MENLO PARK, CA 94025
Title of Security | Transaction Date | 2a. Deemed Execution Date | Transaction Code | Shares | Acquired or Disposed | Price per share | 5. Amount of Securities Beneficially Owned Following Reported Transaction | 6. Ownership Form Direct or Indirect | Nature of Indirect Ownership |
---|---|---|---|---|---|---|---|---|---|
COMMON STOCK, $0.0001 PAR VALUE | 2020-05-27 | S | 7,840 | a | $0.00 | 78,401 | direct | ||
COMMON STOCK, $0.0001 PAR VALUE | 2020-05-27 | 0 | $0.00 | 6,113,134 | indirect | f2 |
Title of Derivative Security | Conversion or Exercise Price of Derivative Security | Transaction Date | Deemed Execution Date | Transaction Code | Number of Derivative Securities Acquired (A) or Disposed of (D) | Date Exercisable | Expiration Date | Title and Amount of Securities Underlying Derivative Security | Price of Derivative Security | Number of derivative Securities Beneficially Owned Following Reported Transaction(s) | Ownership Form: Direct (D) or Indirect (I) | Nature of Indirect Beneficial Ownership |
---|---|---|---|---|---|---|---|---|---|---|---|---|
STOCK OPTION (RIGHT TO BUY) | 17.11 | 2020-05-27 | deemed execution date | A | 15,398 (a) | 2030-05-26 | common stock 15,398 | $17.11 | 15,398 | direct |
ID | footnote |
---|---|
f1 | these shares represent restricted stock units ("rsus") and will be settled in common stock upon vesting. the rsus vest on the earlier of (i) the first anniversary of the grant date or (ii) the date of the 2021 annual meeting of the issuer's stockholders, assuming continuous service as a director until such vesting date. |
f2 | reflects shares held by longitude venture partners ii, l.p. ("lvp2"). longitude capital partners ii, llc ("lcp2") is the general partner of lvp2 and may be deemed to share voting and investment power over the shares of the issuer held by lvp2. patrick g. enright is a managing member of lcp2 and in his capacity as such may be deemed to share voting and investment power over the shares held by lvp2. mr. enright disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein. |
f3 | the shares subject to the option will vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of (i) the first anniversary of the grant date or (ii) the date of the 2021 annual meeting of the issuer's stockholders, assuming continuous service as a director until such vesting date. |